UK Health Radio Podcast
UK Health Radio Podcast
3: Peter Hofland, Ph.D - The Onco’Zine Brief - Episode 3
3: Peter Hofland, Ph.D - The Onco’Zine Brief - Episode 3
3: Peter Hofland, Ph.D - The Onco’Zine Brief - Episode 3
Sunday 26th March 2023
Peter Hofland and Dr. Matthias Bucerius explore how antibody drug conjugates could revolutionize cancer treatment on The Onco'Zine Brief.
42 minutes
Informative
Thought-provoking
Educational
Engaging
Transformative
About this podcast
Overview:
Categories:
Mindfulness & Emotional Wellbeing
Spiritual & Personal Growth Journeys
Mindful Recovery
Entrepreneurship for Personal Growth
Navigating Intimate Relationships
Links:
Visit site
Episodes:
2867 (View all)
Do you want to link to this podcast?
Get the buttons here!Breaking New Ground in Cancer Treatment with Antibody Drug Conjugates
I think we've learned a lot about Adcs and what is really important in the development and manufacturing of these highly targeted and very complex pharmaceutical drugs.
Cancer treatment is evolving, and this episode of The Onco'Zine Brief with Peter Hofland, Ph.D., shines a spotlight on one of the most promising advancements: antibody drug conjugates (Adcs). Dr. Matthias Bucerius, Vice President and General Manager at Merck KGaa, joins Hofland to discuss the groundbreaking potential of Adcs in the fight against cancer. Adcs are complex, combining three functional elements to deliver targeted treatment directly to cancer cells, minimizing damage to healthy tissues.
But developing these sophisticated drugs isn't without its challenges. From intricate supply chains to high-potency manufacturing, the journey of Adcs from concept to market is a meticulous process. Dr. Bucerius shares his insights on overcoming these hurdles and emphasizes the importance of communication and innovation in drug development. This episode is a must-listen for anyone interested in the future of cancer treatment, offering a comprehensive look at how Adcs could revolutionize the way we approach this formidable disease.